FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

34241111000001104: MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 26-Apr 2017. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
103902401000001118 MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
103902501000001119 MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Is a Magnesium glycerophosphate (magnesium 121.25mg/5ml (5mmol/5ml)) oral solution 200 ml true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has AMP MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has specific active ingredient Magnesium glycerophosphate true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has dispensed dose form Conventional release oral solution true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Magnesium true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Legal category Legal category not applicable true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Discontinued indicator Never discontinued true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Is a Actual medicinal product pack true Inferred relationship Existential restriction modifier
MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has basis of strength substance Magnesium true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group

This concept is not in any reference sets

Back to Start